Fortrea Holdings (FTRE) Liabilities from Discontinued Operations (2023 - 2024)
Fortrea Holdings (FTRE) reported Liabilities from Discontinued Operations of 31500000.0 for Q1 2024, down 40.0% quarter-over-quarter from 52500000.0 in Q4 2023.
Fortrea Holdings (FTRE) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Fortrea Holdings has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 31500000.0 in Q1 2024.
- For the quarter ending Q1 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 31500000.0; the trailing twelve-month figure through Mar 2024 stood at 31500000.0 (changed N/A YoY), and the FY2023 full-year result was 52500000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2024 stood at 31500000.0, down from 52500000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 52500000.0 in Q4 2023, with the low at 31500000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 31.50 Mn |
| Mar 31, 2024 | 31.50 Mn |
| Dec 31, 2023 | 52.50 Mn |
| Dec 31, 2023 | 52.50 Mn |